查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2023年至2028年非PVC输液袋市场预测
市场调查报告书
商品编码
1410087

2023年至2028年非PVC输液袋市场预测

Non-PVC IV Bags Market - Forecasts from 2023 to 2028
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 141 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

2021年全球非PVC输液袋市场规模为11.49亿美元。

预计非 PVC IV 袋市场将在整个预测期内稳定成长。由聚氯乙烯 (PVC) 以外的材料製造的输液袋称为非 PVC 输液袋。非 PVC 输液袋通常由对人体风险较低的材料製成，例如聚烯烃、聚氨酯和磺酸盐。非PVC输液袋市场是由癌症患者和肾衰竭等慢性疾病数量的增加所推动的。

癌症患者增加

非PVC输液袋市场受到人口中癌症患者数量不断增加以及对癌症治疗过程（尤其是化疗和标靶药物输送）快速增长的需求的影响。例如，2020 年，六分之一的死亡者，约 1000 万人，死于癌症，根据世界卫生组织的数据，癌症是全球死亡的主要原因。据估计，低收入和中等收入国家 30% 的癌症病例是由人类乳突病毒 (HPV) 和肝炎等致癌感染疾病引起的。非 PVC 输液袋可以安全使用，因为它们造成的污染危害较小。

慢性病增加

需要透析的肾衰竭等慢性疾病的增加预计将在未来几年推动非 PVC IV 袋市场的发展。例如，美国有 3700 万成年人患有慢性肾臟病(CKD)，即超过七分之一的人患有慢性肾臟病。对于患有肾臟疾病的两个主要原因之一（糖尿病或高血压）的美国来说，慢性肾臟病的风险甚至更高。此外，根据世界卫生组织 (WHO) 2022 年更新，慢性阻塞性肺病(COPD) 是全球第三大死因，低收入和中等收入(LMIC) 国家每年约有90 人死于15 岁以下的疾病. 70% 的人死亡。由于接受心臟心血管手术或接受急性加重治疗的患者对用于静脉输液的非 PVC IV 袋的需求预计会增加，预计该市场将会开拓。

政府努力增加非 PC IV 袋的使用

有关 PVC 使用和处置的严格规定以及新兴国家医疗基础设施的改善也推动了非 PVC 输液袋市场的发展。欧洲、美国、加拿大和日本的多个政府机构和专家小组已确定，使患者接触 DEHP 的医疗程序可能会对患者造成健康风险。例如，为了保护早产儿和新生儿，德国联邦药品和医疗设备研究所 (BfArM)建议不要使用由 DEHP 软化 PVC 製成的医疗设备。此外，BfArM 呼吁医疗设备製造商揭露其产品含有 DEHP，并投入时间和精力来创造更安全的替代品。

市场机会

预计上述成长要素将为非 PVC IV 袋市场的扩张提供重大机会。除了这些因素之外，患者对塑胶袋有害影响的认识不断提高，进一步显示非 PVC 输液袋市场的成长。 PVC材料常用于包装。然而，由于它们无法分解，它们的处置会对环境产生负面影响。日益严重的环境问题导致了 PVC 环保替代品的开发，这推动了全球非 PVC IV 袋市场的扩张。例如，为了促进整个欧洲医疗保健的永续性，VinylPlus Med 于 2021 年 10 月在比利时正式启动了医用 PVC 回收试点计画。该计划回收废弃的一次性 PVC医疗设备，包括氧气罩面罩、麻醉面罩、管道、静脉滴注和透析袋。

市场抑制因素

预计很少有因素会限制非 PVC IV 袋市场的成长。在输注药物水溶液过程中，从 PVC 管中洗脱出来的 DEHP 分子会对健康产生许多不利影响，包括但不限于人类代谢紊乱。此外，非 PVC 输液器不含 DEHP 分子，可能会导致不良的健康影响。

北美地区预计将大幅成长

在预测期内，北美地区预计将占据非 PVC IV 袋市场的主要份额。造成这一比例的因素包括癌症患者数量的增加、对 PVC IV 袋有害影响的认识以及严格的政府法规。例如，根据美国癌症协会的数据，预计 2023 年美国将诊断出约 190 万例新癌症病例。根据 FDA 安全评估和公共卫生通告，美国食品药物管理局建议某些易感族群使用含 DEHP 装置的替代品。此外，Baxter 和 ICU Medical 等市场领导的出现预计将进一步推动该地区的非 PVC IV 袋市场。

主要市场参与者

百特透过急诊、营养、肾臟病和外科护理产品改善世界各地的医疗保健。我们提供200 多种输液治疗，包括Viflex 和Viaflo 容器中的0.9% 氯化钠注射液（非PVC）、注射用葡萄糖、乳酸林格氏液和林格氏液、奥米特罗、等离子光、无菌水、葡萄糖用氯化钾和钠注射液提供有效代码。我们也为药物重组系统提供输液解决方案。 ICU Medical 是一家总部位于美国的医疗公司，专门从事静脉治疗。该公司的输液配方在美国的美国工厂生产，只需一到两天即可可靠交付。该公司提供 Supercath 5 IV 导管、Y 型连接器、带 Clave(TM) 的小瓶适配器、双母头连接器、Supercath 5 IV 导管等。

市场主要发展

2022 年 6 月，Gufic Biosciences 在印度推出了带有可剥离铝箔的聚丙烯（不含 DEHP）双腔室袋。这些袋子可以就地储存需要在给药前立即重新配製的不稳定药物。这是一种全新的药物传输技术，印度希望将其本土化。 2021 年 9 月，B.Braun 首次在美国市场推出了可选 AirStop 的非 PVC IV 套装 CARESAFE IV 管理套装。由于它只允许液体通过，因此可以防止管路干燥。 2020年11月，Fagron Stellail Services推出了一个名为静脉（IV）袋的新产品平台，以在2021年继续扩展产品系列。该公司承诺 98% 的准时交货率和供应协议，提供单独包装的产品，以延长保质期并保护产品。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表

第二章调查方法

  • 调查资料
  • 先决条件

第三章执行摘要

  • 研究亮点

第四章市场动态

  • 市场驱动因素
  • 市场抑制因素
  • 波特五力分析
  • 产业价值链分析

第五章非PVC输液袋市场：副产品

  • 介绍
  • 单室
  • 多室

第六章非PVC输液袋市场：依材料分类

  • 介绍
  • 乙烯醋酸乙烯酯
  • 聚丙烯
  • 共聚酯醚
  • 其他的

第七章 非 PVC 输液袋市场：依内容分类

  • 介绍
  • 冷冻混合物
  • 液体混合物

第八章非PVC输液袋市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章竞争环境及分析

  • 主要企业及策略分析
  • 新兴企业和市场盈利
  • 合併、收购、协议和合作
  • 供应商竞争力矩阵

第十章 公司简介

  • Baxter
  • B. Braun Melsungen AG
  • ICU Medical
  • Fresenius Kabi AG
  • JW Life Science
  • RENOLIT
  • PolyCine GmbH
  • Sealed Air
  • ANGIPLAST PVT. LTD
简介目录
Product Code: KSI061615772

The global non-PVC IV bags market was valued at US$1.149 billion in 2021.

The non-PVC IV bags market is anticipated to grow at a steady pace throughout the forecast period. Intravenous bags produced from substances other than polyvinyl chloride (PVC) are known as non-PVC IV bags. Non-PVC IV bags are often created from substances that are less dangerous to human health, such as polyolefins, polyurethane, and polyethersulfone. The rising number of cancer cases and other chronic diseases such as kidney failure are major factors in the non-PVC IV bags market as the therapy in the treatments in these conditions requires IV bags.

Rising Cancer Cases

The non-PVC IV bags market is impacted by the growth in cancer cases in the population as well as the surge in demand for oncology processes, particularly for chemotherapy and targeted drug delivery. For instance, one in six deaths, or around 10 million deaths, was due to cancer in 2020, making it the top cause of death globally as per the WHO. In low and lower-middle-income nations, cancer-causing infections including the human papillomavirus (HPV) and hepatitis are estimated to be the cause of 30% of cancer cases. Non-PVC IV bags are less harmful concerning the contamination thus it is safe to use non-PVC IV bags.

Growing Burden of Chronic Diseases

The growing prevalence of chronic diseases such as kidney failure which require dialysis is expected to drive the non-PVC IV bags market in the coming years. For instance, in the United States, 37 million adults which is more than 1 in 7 have chronic kidney disease (CKD). The risk of CKD is even higher for Americans who have either diabetes or high blood pressure, the two main causes of kidney disease. Moreover, chronic obstructive pulmonary disease (COPD), the third highest cause of mortality globally, kills approximately 90% of those under the age of 70 in low- and middle-income (LMIC) countries, according to World Health Organisation (WHO) updates 2022. Due to the predicted rise in demand for non-PVC IV bags used to provide intravenous fluids to patients undergoing heart surgery and those being treated for acute exacerbations, the market is expected to develop.

Government Efforts to Increase the Use of Non-PC IV Bags

The non-PVC IV bags market is also being boosted by rigorous regulations governing the use and disposal of PVC and improved healthcare infrastructure in developing nations. It has been determined by several government agencies and expert panels in Europe, the US, Canada, and Japan that several medical treatments that expose patients to DEHP may be harmful to their health. For instance, to protect premature infants and newborns, the German Federal Institute for Drugs and Medical Equipment (BfArM) advises against using medical equipment made of DEHP-softened PVC. Additionally, BfArM asks producers of medical devices to disclose the presence of DEHP in their goods and to invest more time and energy in creating safer substitutes.

Opportunities in the Market

These growth factors mentioned above are predicted to provide an immense opportunity in the non-PVC IV bags market expansion. Apart from these factors, the growing awareness among patients about the harmful effects of plastic bags further indicates the growth in the non-PVC IV bags market. Packaging frequently uses PVC materials. However, because they cannot decompose, their disposal has a detrimental effect on the environment. Due to growing environmental concerns, eco-friendly PVC replacements are being developed, which is fueling the expansion of the non-PVC IV bag market globally. For instance, to advance sustainability in healthcare across Europe, VinylPlus Med officially inaugurated its pilot medical PVC recycling program in Belgium in October 2021. This program will recycle discarded single-use PVC medical devices, such as oxygen and anaesthetic masks, tubing, IVs, and dialysis bags.

Restraints in the Market

Few factors are expected to limit the non-PVC IV bags market growth. The leached DEHP molecules from the PVC tube during intravenous infusion of aqueous drug solutions produce many harmful health effects, including but not limited to a disruption in human metabolism. Additionally, non-PVC infusion sets do not carry the DEHP molecules, which causes unfavourable health effects.

North America is Expected to Grow Significantly

The North American region is supposed to hold a significant share of the non-PVC IV bags market during the forecast period. Various factors attributed to such a share are rising cancer cases, awareness about the hazardous effects of PVC IV bags, and stringent government regulations. For instance, around 1.9 million new cancer cases are anticipated to be diagnosed in 2023 in the US as per the American Cancer Society. Using alternatives to DEHP-containing devices for specific, susceptible individuals is advised by the US Food and Drug Administration, according to an FDA Safety Assessment and a Public Health Notification. Moreover, the presence of market leaders such as Baxter and ICU Medical is further predicted to propel the non-PVC IV bags market in the region.

Major Market Players

  • Baxter offers a range of acute, nutritional, renal, and surgical care products to advance healthcare around the globe. It offers more than 200 active codes for fluid therapy such as 0.9% sodium chloride injection in both Viflex and Viaflo containers (non-PVC), dextrose for injection, lactated ringers & ringers, OSMITROL, Plasmalyte, sterile water, and potassium chloride in dextrose & sodium injections. It also provides an IV solution for the drug reconstitution system.
  • ICU Medical, a US-based medical company focussed on IV therapy. Its IV solutions are produced in two US plants with reliable delivery in just one to two days in the US. It offers Supercath 5 IV Catheter, Y-Connector, Vial Adapter with Clave™, Double Female Connector, Supercath 5 IV Catheter, and others.

Key Market Developments

  • In June 2022, dual chamber IV bags made of polypropylene (DEHP free) with a peelable aluminium foil were introduced by Gufic Biosciences in India. These bags allow the storage of unstable medications that need to be reconstituted right before administration at the point. This is a brand-new medicine delivery technology that India intends to produce domestically.
  • In September 2021, B.Braun launched a non-PVC IV set, CARESAFE IV Administration Sets with optional AirStop to reduce patient exposures to toxic substances which was the first in the US market. It helps keep the line from drying out because it is made to only let fluid pass.
  • In November 2020, Fagron Sterile Services launched a new product platform named Intravenous (IV) Bags for the continued expansion of its product portfolio in 2021. It is committed to supply agreements offered with a 98% on-time delivery rate and products individually wrapped for extended beyond-use dating and product protection.

Segmentation:

By Product

  • Single Chamber
  • Multi-Chamber

By Material

  • Ethylene Vinyle Acetate
  • Polypropylene
  • Copolyester ether
  • Others

By Content

  • Frozen Mixture
  • Liquid Mixture

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. NON-PVC IV BAGS MARKET, BY PRODUCT

  • 5.1. Introduction
  • 5.2. Single Chamber
  • 5.3. Multi Chamber

6. NON-PVC IV BAGS MARKET, BY MATERIAL

  • 6.1. Introduction
  • 6.2. Ethylene Vinyle Acetate
  • 6.3. Polypropylene
  • 6.4. Copolyester ether
  • 6.5. Others

7. NON-PVC IV BAGS MARKET, BY CONTENT

  • 7.1. Introduction
  • 7.2. Frozen Mixture
  • 7.3. Liquid Mixture

8. NON-PVC IV BAGS MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. The Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Emerging Players and Market Lucrativeness
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

  • 10.1. Baxter
  • 10.2. B. Braun Melsungen AG
  • 10.3. ICU Medical
  • 10.4. Fresenius Kabi AG
  • 10.5. JW Life Science
  • 10.6. RENOLIT
  • 10.7. PolyCine GmbH
  • 10.8. Sealed Air
  • 10.9. ANGIPLAST PVT. LTD